Specific Suppression Of MYCN Gene In Neuroblastoma Cell By MYCN SiRNA

Background: Neuroblastoma is the most common extracranial malignant solid tumor in infants and children. Some infants with neuroblastoma tend to present with lower stage disease (stages 1, 2, and 4s), a proportion of lower stage tumours with non-MYCN amplification show spontaneous regression, even those showing widespread dissemination in stage 4s disease. However some patients in stage 4s with MYCN amplification show bad outcome. MYCN amplification is one of the key predictors of poor outcome in this disease. MYCN oncogene is associated with advanced-stage disease, rapid tumor progression, resistance to treatment, and poor outcome. The frequent amplification of the MYCN gene, makes MYCN an potential therapeutic target in gene therapy of neuroblastoma. RNA interference is an evolutionarily conserved mechanism in plant and animal cells that directs the degradation of messenger RNAs homologous to short double-stranded RNAs termed small interfering RNA (siRNA). The ability of siRNA to direct gene silencing in mammalian cells has raised the possibility that siRNA might be used to suppress gene expression in human diseases. People can design siRNA against MYCN oncogene. Quantitative reverse transcriptase-polymerase chain reaction with SYBR GREEN I fluorescence is a reliable method for detection of gene expression.Objective: To see if RNAi suppress the MYCN expression and these change the growth behavior of LAN-5Methods: Establish quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) with SYBR GREEN I system. RNA was isolated...